安罗替尼辅助适形调强放疗同步化疗在肺癌脑转移患者临床治疗中的应用效果  

Effect of Anlotinib Assisted Conformal Intensity Modulated Radiotherapy and Synchronous Chemotherapy in the Clinical Treatment of Lung Cancer Patients with Brain Metastases

作　　者：李慧 许聪聪 张冬冬 LI Hui;XU Congcong;ZHANG Dongdong(Department of Oncology,Shandong Guoxin Yiyang Group Zaozhuang Hospital,Zaozhuang 277100,China)

机构地区：[1]山东国欣颐养集团枣庄医院肿瘤内科,山东枣庄277100

出　　处：《反射疗法与康复医学》2024年第15期104-107,共4页Reflexology And Rehabilitation Medicine

摘　　要：目的探讨肺癌脑转移患者采用安罗替尼辅助适形调强放疗同步化疗的效果。方法回顾性分析2021年1月—2022年11月在山东国欣颐养集团枣庄医院接受治疗的100例肺癌脑转移患者的临床资料,根据治疗方案不同将其分为对照组及观察组。将行适形调强放疗同步化疗的50例作为对照组,将行安罗替尼辅助适形调强放疗同步化疗的50例作为观察组,均治疗2个周期。比较两组患者的疗效、肿瘤标志物水平、不良反应发生情况及预后情况。结果观察组的疾病控制率为92.00%,高于对照组的70.00%,差异有统计学意义(P<0.05)。治疗后,观察组的血清癌胚抗原、鳞状上皮细胞癌抗原水平均低于对照组,组间差异有统计学意义(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。观察组的总生存期、无进展生存期均长于对照组,组间差异有统计学意义(P<0.05)。结论肺癌脑转移患者采用安罗替尼辅助适形调强放疗同步化疗的效果满意,可降低肿瘤标志物水平,改善预后。Objective To investigate the effect of anlotinib assisted conformal intensity modulated radiotherapy and synchronous chemotherapy in patients with brain metastasis of lung cancer.Methods The clinical data of 100 patients with brain metastasis of lung cancer who were treated in Shandong Guoxin Yiyang Group Zaozhuang Hospital from January 2021 to November 2022 were retrospectively analyzed,and they were divided into a control group and an observation group according to different treatment regimens.50 cases receiving conformal intensity modulated radiotherapy synchronous chemotherapy were taken as the control group,and 50 cases receiving anlotinib assisted conformal intensity modulated radiotherapy synchronous chemotherapy were taken as the observation group.Both groups were treated for 2 cycles.The efficacy,tumor marker levels,the occurrence of adverse reactions and the prognosis of the two groups were compared.Results The disease control rate of the observation group was 92.00%,higher than 70.00%of control group,the difference was statistically significant(P<0.05).After treatment,the levels of carcinoembryonic antigen and squamous cell carcinoma antigen in the observation group were lower than those in the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The overall survival and progression-free survival of the observation group were longer than those of the control group,and the differences between the groups were statistically significant(P<0.05).Conclusion The effect of anlotinib assisted conformal intensity modulated radiotherapy and synchronous chemotherapy is satisfactory,which can reduce the levels of tumor markers and improve the prognosis of lung cancer patients with brain metastases.

关 键 词：肺癌 脑转移 适形调强放疗 化疗 安罗替尼 

分 类 号：R734.2[医药卫生—肿瘤]